



RECEIVED

JUL 0 9 2001

1644

TECH CENTER 1600/2900

AMENDED TRANSMITTAL LETTER			DOCKET NUMBER: P-UW 3570	
SERIAL NO: 09/323,738	FILING DATE: June 1, 1999	EXAMINER: F. VanderVegt	GROUP ART UNIT: 1644	
INVENTION: COMPOSITIONS AND METHODS FOR TREATING DIABETES				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on June 27, 2001.

By: David A. Gay
David A. Gay, Reg. No. 39,200

June 27, 2001
Date of Signature

Transmitted herewith is a Response to Office Action mailed March 28, 2001, with attached Appendix A, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☐ Petition for Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMEND- MENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE		
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	40-20	-	40	-	0	x	\$9	\$18	=	\$0	\$
INDEPEN- DENT CLAIMS	4-3	-	4	-	0	x	\$40	\$80	=	\$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		_____YES		_____X_____NO			\$135	\$270	=	\$0	\$
							TOTAL ADDITIONAL FEE			\$0	\$

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

____ Please charge my Deposit Account No. 03-0370 the amount of \$ _____. A duplicate copy of this sheet is enclosed.

Inventors: Osborne and Ramesh
Serial No.: 09/323,738
Filed: June 1, 1999
Page 2

— A check in the amount of \$ is enclosed, \$ of which covers the fee for a -month extension of time.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.


X Any additional filing fees required under 37 C.F.R. 1.16.

X Any patent application processing fees under 37 C.F.R. 1.17.

X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

June 27, 2001
Date



David A. Gay
Registration No. 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601

RECEIVED

JUL 09 2001

TECH CENTER 1600/2900

PATENT

Our Docket: P-UW 3570



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Osborne and Ramesh

Serial No: 09/323,738

Filed: June 1, 1999

For: COMPOSITIONS AND METHODS
FOR TREATING DIABETES

Commissioner for Patents
Washington, D.C. 20231

Group Art Unit: 1644

Examiner: F. VanderVegt

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Washington, D.C., 20231 on
June 27, 2001.

By: David A. Gay
David A. Gay, Reg. No. 39,200

June 27, 2001
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed March 28, 2001,
entry of the following Amendments and Remarks is respectfully
requested.

AMENDMENTS

Please amend the claims as follows:

17. (Amended) A method of treating diabetes or
forestalling a clinical symptom indicative of diabetes
comprising implanting into an individual cells coexpressing
proinsulin containing a proinsulin cleavage site and a glucose-
regulated protease capable of cleaving said proinsulin cleavage
site to produce insulin.

28. (Amended) A method of treating diabetes or
forestalling a clinical symptom indicative of diabetes comprising